# Rondo Therapeutics

Source: https://onco.cc/companies/rondo-therapeutics/  
OnCo record `rondo-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rondo Therapeutics makes two-armed antibodies that grab a tumour protein with one arm and give T cells an extra activation signal with the other, so the immune system attacks solid tumours. Its first drug, RNDO-564, is in an early trial for bladder cancer and other tumours that carry Nectin-4.

## Summary

Rondo Therapeutics, at 25801 Industrial Boulevard, Hayward, California, was co-founded by chief executive Shelley Force Aldred and chief scientific officer Nathan Trinklein and develops immune-cell engaging bispecific antibodies for solid tumours using an NGS-based antibody discovery platform with a fixed light-chain format. The lead candidate RNDO-564 is a CD28 x Nectin-4 bispecific, tested alone and with pembrolizumab in a phase 1/1b study in bladder cancer and other Nectin-4 associated solid tumours, including non-small cell lung, cervical, head and neck and triple-negative breast cancers. Earlier programmes pair CD3 and CD28 arms with undisclosed targets for ovarian, endometrial and renal cancers, and the company announced a collaboration with Lilly on CD28 bispecific antibodies in December 2024. Its first registered cancer trial, NCT07218003, was posted on ClinicalTrials.gov in October 2025. In March 2022 it closed a USD 67 million Series A co-led by Red Tree Venture Capital and Canaan Partners with Johnson & Johnson Innovation (JJDC), Novo Holdings and SV Health Investors.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Hayward, CA
- Type: biotech
- Website: https://www.rondotx.com/

## Notes

- Founding year not stated on the company website.
- The Lilly collaboration is listed from its headline on the company website; terms were not read.
-  CD28 bispecifics are costimulatory rather than CD3 T-cell engagers, so the record links the bispecific antibody record only.
- Company website and the 2022 Series A release read on 29 October 2026.

## Sources

- Official website: https://www.rondotx.com/
- Collaboration with Lilly on CD28 bispecific antibodies, December 2024: https://www.businesswire.com/news/home/20241204127623/en/Rondo-Therapeutics-Announces-Collaboration-with-Lilly-to-Develop-Novel-CD28-Bispecific-Antibodies-for-Solid-Tumors
- ClinicalTrials.gov: phase 1/1b trial of RNDO-564 alone or with pembrolizumab (NCT07218003): https://clinicaltrials.gov/study/NCT07218003

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/)
- targets: [CD28](https://onco.cc/targets/cd28/), [Nectin-4](https://onco.cc/targets/nectin4/)
- trials: [RNDO-564 alone or with pembrolizumab](https://onco.cc/trials/nct07218003/)
- companies: [Johnson & Johnson Innovation - JJDC](https://onco.cc/companies/jjdc/), [Novo Holdings](https://onco.cc/companies/novo-holdings/), [SV Health Investors](https://onco.cc/companies/sv-health-investors/)

---
JSON: https://onco.cc/api/v1/entities/rondo-therapeutics.json